MY199409A - N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors - Google Patents
N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitorsInfo
- Publication number
- MY199409A MY199409A MYPI2019000239A MYPI2019000239A MY199409A MY 199409 A MY199409 A MY 199409A MY PI2019000239 A MYPI2019000239 A MY PI2019000239A MY PI2019000239 A MYPI2019000239 A MY PI2019000239A MY 199409 A MY199409 A MY 199409A
- Authority
- MY
- Malaysia
- Prior art keywords
- bcl
- benzamides
- phenylsulfonyl
- inhibitors
- related compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- ZBGWAJQUDSCDPB-UHFFFAOYSA-N n-(benzenesulfonyl)benzamide Chemical class C=1C=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1 ZBGWAJQUDSCDPB-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY199409A true MY199409A (en) | 2023-10-25 |
Family
ID=59677319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019000239A MY199409A (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (https=) |
| EP (3) | EP3569601B1 (https=) |
| JP (2) | JP6651180B2 (https=) |
| KR (2) | KR102376764B1 (https=) |
| CN (2) | CN109311871B (https=) |
| AU (2) | AU2017305508B2 (https=) |
| CA (1) | CA3031419C (https=) |
| CY (1) | CY1123859T1 (https=) |
| DK (1) | DK3494115T3 (https=) |
| ES (1) | ES2849959T3 (https=) |
| HR (1) | HRP20202073T1 (https=) |
| HU (1) | HUE053414T2 (https=) |
| IL (2) | IL264059B (https=) |
| LT (1) | LT3494115T (https=) |
| MX (2) | MX381588B (https=) |
| MY (1) | MY199409A (https=) |
| PE (1) | PE20190711A1 (https=) |
| PH (1) | PH12019500231A1 (https=) |
| PT (1) | PT3494115T (https=) |
| RS (1) | RS61821B1 (https=) |
| RU (2) | RU2744358C2 (https=) |
| SA (1) | SA519401020B1 (https=) |
| SG (2) | SG11201900135YA (https=) |
| SI (1) | SI3494115T1 (https=) |
| SM (1) | SMT202100025T1 (https=) |
| WO (1) | WO2018027097A1 (https=) |
| ZA (2) | ZA201900240B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3426655A1 (en) * | 2016-03-10 | 2019-01-16 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| KR102376764B1 (ko) * | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) * | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| CA3094449C (en) * | 2018-07-31 | 2023-02-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| TWI725488B (zh) * | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| JP2021516262A (ja) * | 2018-07-31 | 2021-07-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果 |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3706741A4 (en) * | 2018-11-23 | 2022-03-30 | Ascentage Pharma (Suzhou) Co., Ltd. | PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| TW202114664A (zh) * | 2019-07-31 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | Ｂｃｌ－２／Ｂｃｌ－ｘＬ抑制劑與化療藥的組合產品及其在預防和／或治療疾病中的用途 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| US12287338B2 (en) | 2019-11-27 | 2025-04-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
| WO2021110097A1 (en) | 2019-12-03 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| WO2021110136A1 (en) * | 2019-12-04 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| KR20220100992A (ko) | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
| EP3914596A4 (en) * | 2020-03-06 | 2022-04-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates |
| US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
| JP7839962B2 (ja) | 2020-04-15 | 2026-04-03 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｂｃｌ－２阻害剤 |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| WO2022002178A1 (en) * | 2020-07-01 | 2022-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| US20230250077A1 (en) * | 2020-07-10 | 2023-08-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| CN114533677A (zh) * | 2020-11-25 | 2022-05-27 | 苏州亚盛药业有限公司 | 固体分散体、制剂、其制备方法及其应用 |
| US20240316069A1 (en) * | 2020-12-28 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
| EP4298098A4 (en) * | 2021-02-01 | 2025-06-25 | Ascentage Pharma (Suzhou) Co., Ltd. | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| EP4382126A4 (en) | 2021-08-02 | 2025-07-30 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND ITS USE |
| EP4442685A4 (en) * | 2021-12-06 | 2025-11-19 | Hangzhou Healzen Therapeutics Co Ltd | BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| WO2024184233A1 (en) | 2023-03-03 | 2024-09-12 | Ionctura Sa | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| RU2009125575A (ru) | 2006-12-04 | 2011-01-20 | Эбботт Лэборетриз (Us) | Комплексные диагностические анализы для терапии рака |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| MX2011008488A (es) | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
| NZ595708A (en) * | 2009-05-26 | 2014-03-28 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| CA3152557A1 (en) * | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| TWI620736B (zh) * | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| PT2643322T (pt) * | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| WO2017117416A1 (en) | 2015-12-30 | 2017-07-06 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile |
| KR102376764B1 (ko) * | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
-
2017
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| MX2023006257A (es) | Inhibidores de smyd. | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| MX384905B (es) | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
| JOP20190076B1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| WO2015200680A3 (en) | Prmt5 inhibitors and uses thereof | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| WO2018044767A3 (en) | Aminopyrimidines as alk inhibitors | |
| EA201591781A1 (ru) | Химические соединения | |
| WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. |